New drug aims to curb impulsive behavior in opioid addiction

NCT ID NCT06628622

Terminated Symptom relief Sponsor: Boehringer Ingelheim Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 31, 2026 · Updated 2 times

Summary

This early-stage trial tests whether a daily tablet called BI 1356225 can improve impulse control in people with opioid use disorder who are already taking buprenorphine. About 60 participants will be randomly assigned to receive either the study drug or a placebo for 8 days. Researchers will measure impulsivity using computer tasks and questionnaires, and monitor safety closely.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BI 1356225
What this could lead to: If it works, this could point toward a new treatment to help people with opioid addiction better control impulses and reduce risky behaviors.
What could go wrong: This is a very early Phase 1 trial with only 60 people, so it may not show a clear benefit. The study is also currently suspended, which could indicate challenges.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OPIOID-USE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

opiate dependence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OPIOID-USE DISORDER

Contacts and locations

Locations

Collaborative Neuroscience Research, LLC, Los Alamitos

Los Alamitos, California, 90720, United States
Hassman Research Institute-Marlton-66897

Marlton, New Jersey, 08053, United States
University of California Los Angeles

Los Angeles, California, 90095, United States
Virginia Commonwealth University

Richmond, Virginia, 23298, United States
iResearch Atlanta

Decatur, Georgia, 30030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.